Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics DOI Creative Commons
N. Sanoj Rejinold, Geun‐woo Jin, Jin‐Ho Choy

et al.

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 23, 2025

Abstract Niclosamide, initially developed as an anthelmintic, has recently emerged a potential antiviral, showing efficacy against diverse viral threats, including Mpox. As the global health landscape faces recurrent Mpox outbreaks, repurposing niclosamide through advanced material strategies offers promising therapeutic avenues. This article explores antiviral mechanisms of niclosamide, focusing on how innovative nano‐hybrid formulations enhance its bioavailability and pharmacological performance. By leveraging nanohybridization, niclosamide's limitations—such poor solubility bioavailability—are addressed, enabling targeted delivery sustained release. Early preclinical studies reveal that disrupts replication entry processes, suggesting utility option poxvirus infections. Looking forward, further in vitro, animal models, clinical investigations are essential to optimize application dosing for With continued development materials, nanohybrid could become critical tool managing related offering accessible, cost‐effective outbreak preparedness.

Language: Английский

Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics DOI Creative Commons
N. Sanoj Rejinold, Geun‐woo Jin, Jin‐Ho Choy

et al.

Advanced Healthcare Materials, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 23, 2025

Abstract Niclosamide, initially developed as an anthelmintic, has recently emerged a potential antiviral, showing efficacy against diverse viral threats, including Mpox. As the global health landscape faces recurrent Mpox outbreaks, repurposing niclosamide through advanced material strategies offers promising therapeutic avenues. This article explores antiviral mechanisms of niclosamide, focusing on how innovative nano‐hybrid formulations enhance its bioavailability and pharmacological performance. By leveraging nanohybridization, niclosamide's limitations—such poor solubility bioavailability—are addressed, enabling targeted delivery sustained release. Early preclinical studies reveal that disrupts replication entry processes, suggesting utility option poxvirus infections. Looking forward, further in vitro, animal models, clinical investigations are essential to optimize application dosing for With continued development materials, nanohybrid could become critical tool managing related offering accessible, cost‐effective outbreak preparedness.

Language: Английский

Citations

0